After hitting a major regulatory roadblock, DBV Technologies sees a path to approval for its leading candidate.
News & Analysis: DBV Technologies
The company submitted its potential peanut allergy treatment for review in Europe.
Thanks to bad news for its competitor, this company behind the first FDA-approved peanut allergy treatment could be ripe for a rebound.
The FDA rejected the company’s application for its peanut-allergy patch.
The company provided a grim business update.
DBV Technologies and Aimmune are at the finish line for developing novel therapies for treating peanut allergies, but each has its own twist.
A sizable capital raise sent shareholders running for the exits this morning.
Long-term data suggests longer treatments with Viaskin Peanut improve peanut tolerance.
Traders cheered after the company announced the pricing details of a stock offering.
Find out why these stocks stood out on a down day for the market.